Wall Street Zen Upgrades ASP Isotopes (NASDAQ:ASPI) to "Sell"

Key Points

• Wall Street Zen upgraded ASP Isotopes from “strong sell” to “sell,” while Weiss Ratings maintained a “sell (D-)” rating. MarketBeat’s consensus is “Hold,” with an average price target of $13.00.
• ASP Isotopes reported a quarterly loss of $0.28 per share, missing the $0.17 consensus estimate, despite revenue of $5.12 million exceeding expectations. The company continues to show deeply negative margins and return on equity.
• Insiders sold 279,079 shares worth approximately $2.05 million over the past 90 days, while institutional investors—including BlackRock and Encompass Capital—added significant positions.

ASP Isotopes (NASDAQ:ASPI - Get Free Report) was upgraded by Wall Street Zen from a "strong sell" rating to a "sell" rating in a research note issued to investors on Saturday.

Separately, Weiss Ratings reiterated a "sell (d-)" rating on shares of ASP Isotopes in a research report on Wednesday, June 24th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has an average rating of "Hold" and an average target price of $13.00.

ASP Isotopes Price Performance

Shares of NASDAQ:ASPI opened at $4.00 on Friday. ASP Isotopes has a one year low of $3.51 and a one year high of $14.49. The stock has a fifty day moving average of $4.94 and a 200-day moving average of $5.32. The company has a market capitalization of $613.24 million, a PE ratio of -3.03 and a beta of 3.61. The company has a debt-to-equity ratio of 0.76, a quick ratio of 4.37 and a current ratio of 3.87.

ASP Isotopes (NASDAQ:ASPI - Get Free Report) last issued its earnings results on Friday, August 14th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.17) by ($0.11). The company had revenue of $5.12 million during the quarter, compared to analyst estimates of $4.47 million. ASP Isotopes had a negative return on equity of 64.99% and a negative net margin of 427.98%.

Insider Activity

In other news, Director Todd Wider sold 50,000 shares of the firm's stock in a transaction on Monday, June 29th. The shares were sold at an average price of $6.25, for a total transaction of $312,500.00. Following the transaction, the director owned 722,247 shares in the company, valued at approximately $4,514,043.75. This trade represents a 6.47% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Michael Gorley sold 30,000 shares of ASP Isotopes stock in a transaction on Tuesday, June 30th. The shares were sold at an average price of $6.27, for a total transaction of $188,100.00. Following the completion of the sale, the director directly owned 87,908 shares of the company's stock, valued at approximately $551,183.16. The trade was a 25.44% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 279,079 shares of company stock valued at $2,049,208. 14.40% of the stock is currently owned by company insiders.

Institutional Trading of ASP Isotopes

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. BlackRock Inc. bought a new stake in shares of ASP Isotopes during the 2nd quarter worth about $57,331,000. Encompass Capital Advisors LLC bought a new position in shares of ASP Isotopes in the 1st quarter valued at approximately $30,551,000. Alyeska Investment Group L.P. raised its stake in shares of ASP Isotopes by 73.4% in the 4th quarter. Alyeska Investment Group L.P. now owns 4,895,546 shares of the company's stock valued at $26,191,000 after acquiring an additional 2,072,851 shares in the last quarter. Vanguard Group Inc. lifted its holdings in ASP Isotopes by 37.9% in the 3rd quarter. Vanguard Group Inc. now owns 4,516,763 shares of the company's stock worth $43,451,000 after purchasing an additional 1,241,024 shares during the last quarter. Finally, Rovida Investment Management Ltd lifted its holdings in ASP Isotopes by 28.1% in the 4th quarter. Rovida Investment Management Ltd now owns 4,100,000 shares of the company's stock worth $21,894,000 after purchasing an additional 900,000 shares during the last quarter. Institutional investors and hedge funds own 16.80% of the company's stock.

ASP Isotopes Company Profile

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235. ASP Isotopes Inc was incorporated in 2021 and is headquartered in Washington, District Of Columbia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source